Arai Tadashi, Senda Mihoko, Yokoyama Hitomi, Yasuda Kikuko
Department of Internal Medicine, Arai Clinic, Gifu 501-2105;
Exp Ther Med. 2010 Jul;1(4):669-673. doi: 10.3892/etm_00000105. Epub 2010 Jul 1.
In Japan, ambulatory blood pressure monitoring (ABPM) became covered by health insurance in April 2008. In The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2009), the importance of 24-h blood pressure monitoring was also described in an additional section. Therefore, ABPM may be increasingly applied in hypertension treatment. However, in Japan, few studies have presented data on the effects of various anti-hypertensive agents on 24-h blood pressure changes. Irbesartan became commercially available in July 2008 as the sixth angiotensin II type 1 receptor blocker in Japan. In the present study, 24-h blood pressure control was examined using ABPM in Japanese patients with essential hypertension who were treated with irbesartan, and its efficacy was evaluated. This study was completed in 30 of the 32 subjects. This agent decreased both the nocturnal and daytime blood pressures and reduced the rate of change in the systolic blood pressure early in the morning, resulting in favorable blood pressure control. It also significantly decreased the urinary albumin level, suggesting that it exhibits renoprotective effects at doses approved in Japan.
在日本,动态血压监测(ABPM)于2008年4月被纳入医疗保险覆盖范围。在《日本高血压学会高血压管理指南(JSH2009)》中,还在新增章节中阐述了24小时血压监测的重要性。因此,ABPM可能会越来越多地应用于高血压治疗。然而,在日本,很少有研究提供各种抗高血压药物对24小时血压变化影响的数据。厄贝沙坦于2008年7月在日本作为第六种血管紧张素II 1型受体阻滞剂上市。在本研究中,使用ABPM对接受厄贝沙坦治疗的日本原发性高血压患者的24小时血压控制情况进行了检查,并对其疗效进行了评估。本研究在32名受试者中的30名完成。该药物降低了夜间和白天的血压,并降低了清晨收缩压的变化率,从而实现了良好的血压控制。它还显著降低了尿白蛋白水平,表明其在日本批准的剂量下具有肾脏保护作用。